SuperworthTactile Systems Technology TCMD
- Market cap
- $535.5M
- PE
- 21.9×
- 9y median 62.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.5×
- EV/EBIT
- 13.3×
- Revenue, 12 months
- $350.3M
- +17% on a year ago
- Net margin
- 7.1%
- Free cash flow yield
- 5.0%
Tactile Systems Technology trades at 21.9× trailing earnings, cheaper than 75% of the last ten years. Revenue was $350.3M over the last twelve months, up 17% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $69.6M+7% | $77.7M+5% | $61.1M+4% | $73.2M+7% | $73.1M+5% | $85.6M+10% | $61.3M+0% | $78.9M+8% | $85.8M+17% | $103.6M+21% | $75.3M+23% | $85.7M+9% | |
| Cost of revenue | $20.2M+10% | $21.6M−1% | $17.7M+2% | $19.1M−5% | $18.3M−10% | $21.2M−2% | $15.9M−10% | $20.1M+5% | $20.8M+13% | $22.6M+7% | $17.7M+11% | $20.3M+1% |
| Gross profit | $49.4M+6% | $56M+8% | $43.4M+5% | $54.1M+12% | $54.8M+11% | $64.4M+15% | $45.3M+4% | $58.8M+9% | $65M+19% | $81M+26% | $57.6M+27% | $65.3M+11% |
| R&D | $2M+24% | $1.8M−16% | $2.1M−4% | $2.2M+22% | $2.4M+23% | $2M+14% | $1.7M−19% | $2M−10% | $2.2M−9% | $2.5M+24% | $2.8M+59% | $2.5M+24% |
| SG&A | $42.5M−1% | $41.8M+3% | $43.6M+5% | $45.4M+5% | $45M+6% | $49.2M+18% | $47.5M+9% | $52.1M+15% | $51.3M+14% | $59.1M+20% | $55.8M+17% | $55.4M+6% |
| $8M | $11.8M+50% | −$3M−22% | $5.8M+184% | $6.8M−15% | $12.5M+6% | −$4.5M+53% | $4.1M−30% | $11M+62% | $18.8M+50% | −$1.5M−66% | $6.8M+67% | |
| Interest expense | n/a | n/a | $567K | $529K | $517K | $471K | $424K−25% | $410K−23% | $193K−63% | $11K−98% | $28K−93% | $19K−95% |
| Pre-tax income | $7.6M | $11.8M+71% | −$2.8M−42% | $6.1M+398% | $7.2M−5% | $13M+10% | −$4.1M+45% | $4.5M−26% | $11.4M+58% | $19.4M+50% | −$896K−78% | $7.4M+63% |
| −$14.7M+19009% | $3.6M+56% | −$600K−79% | $1.8M+35% | $2.1M | $3.3M−8% | −$1.1M+83% | $1.3M−26% | $3.2M+55% | $8.8M+169% | $867K | −$417K | |
| Net income | $22.3M | $8.2M+78% | −$2.2M+17% | $4.3M | $5.2M−77% | $9.7M+19% | −$3M+35% | $3.2M−25% | $8.2M+59% | $10.6M+9% | −$1.8M−41% | $7.8M+142% |
| $0.94 | $0.35+52% | −$0.09+0% | $0.18 | $0.21−78% | $0.40+14% | −$0.13+44% | $0.14−22% | $0.36+71% | $0.46+15% | −$0.08−39% | $0.34+143% | |
| 23.8M+18% | 23.7M+18% | 23.7M+11% | 24.1M+3% | 24.3M+2% | 24.3M+3% | 23.7M+0% | 23.2M−4% | 22.5M−7% | 23.3M−4% | 22.6M−5% | 23.1M−1% |
Revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Operating income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Income tax: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them. 20 periods, Q1 FY18 to Q1 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 12 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY15: share-days: the 6-month average less the second quarter's. 9 periods, Q4 FY15 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Tactile Systems Technology's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| Peer median | $635.9M | 28.3× | 24.1× | 2.0× | +4% | 7.3% |
More on Tactile Systems Technology
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 33Medical instruments and supplies stocks with the fastest earnings growth
- #10of 46Medical instruments and supplies stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .